Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss

Phase 3

Active, not recruiting

Conditions: Triple Negative Breast Neoplasms

Interventions: Drug: placebo
Drug: alpelisib
Drug: nab-paclitaxel

First Posted Date: 2020-02-05

Last Posted Date: 2024-07-31

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 137

Registration Number: NCT04251533

Locations: 🇺🇸
University Of California LA Santa Monica Location, Los Angeles, California, United States
🇺🇸
Park Nicollet Institute Dept Onc, Saint Louis Park, Minnesota, United States
🇬🇧
Novartis Investigative Site, Oxford, United Kingdom

and more 3 locations

Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL

Phase 1

Terminated

Conditions: Chronic Lymphocytic Leukemia
Non-Hodgkins Lymphoma

Interventions: Drug: JBH492

First Posted Date: 2020-01-27

Last Posted Date: 2024-10-31

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 25

Registration Number: NCT04240704

Locations: 🇪🇸
Novartis Investigative Site, Barcelona, Catalunya, Spain

KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors

Early Phase 1

Terminated

Conditions: Solid Tumors

Interventions: Drug: KAZ954
Drug: NIR178
Drug: PDR001
Drug: NZV930

First Posted Date: 2020-01-23

Last Posted Date: 2024-07-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 77

Registration Number: NCT04237649

Locations: 🇺🇸
University Of California LA, Los Angeles, California, United States
🇺🇸
Northwestern University Med School, Chicago, Illinois, United States
🇺🇸
Uni of TX MD Anderson Cancer Cntr, Houston, Texas, United States

and more 3 locations

A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration

Phase 3

Completed

Conditions: Neovascular Age Related Macular Degeneration

Interventions: Drug: RTH258/Brolucizumab

First Posted Date: 2020-01-23

Last Posted Date: 2024-10-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 210

Registration Number: NCT04239027

Locations: 🇫🇷
Novartis Investigative Site, Toulouse Cedex 9, France

A Study of Secukinumab Treatment in Patients With Plaque Psoriasis and Coexisting Non-alcoholic Fatty Liver Disease (NAFLD)

Phase 3

Terminated

Conditions: Plaque Psoriasis
Non-alcoholic Fatty Liver Disease

Interventions: Biological: Control Arm - placebo
Biological: Investigational Arm - secukinumab

First Posted Date: 2020-01-23

Last Posted Date: 2024-02-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 10

Registration Number: NCT04237116

Locations: 🇪🇸
Novartis Investigative Site, Valencia, Comunidad Valenciana, Spain

Study of Safety, Tolerability and Clinical Outcomes of Egaten in Fascioliasis Patients (6 Years of Age or Older).

Phase 4

Recruiting

Conditions: Fascioliasis

Interventions: Drug: Egaten (Triclabendazole) 250 mg tablets

First Posted Date: 2020-01-18

Last Posted Date: 2024-12-31

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 300

Registration Number: NCT04230148

Locations: 🇻🇳
Novartis Investigative Site, Quy Nhon, Binh Dinh, Vietnam

Study of Efficacy and Safety of Reinfusion of Tisagenlecleucel in Pediatric and Young Adult Patients With Acute Lymphoblastic Leukemia (ALL)

Phase 2

Terminated

Conditions: Acute Lymphoblastic Leukemia

Interventions: Biological: Tisagenlecleucel

First Posted Date: 2020-01-13

Last Posted Date: 2023-01-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 5

Registration Number: NCT04225676

Locations: 🇺🇸
Childrens Hospital Los Angeles Divisionof Hematology/Oncology, Los Angeles, California, United States
🇺🇸
Ann and Robert H Lurie Childrens Hospital of Chicago, Chicago, Illinois, United States
🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States

and more 1 locations

Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab

Phase 3

Terminated

Conditions: Chronic Spontaneous Urticaria

Interventions: Drug: Ligelizumab

First Posted Date: 2019-12-26

Last Posted Date: 2024-06-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1033

Registration Number: NCT04210843

Locations: 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam

Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis

Phase 3

Completed

Conditions: Psoriatic Arthritis

Interventions: Drug: AIN457 6 mg/kg i.v.
Drug: Placebo
Drug: AIN457 3 mg/kg

First Posted Date: 2019-12-24

Last Posted Date: 2024-04-26

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 381

Registration Number: NCT04209205

Locations: 🇹🇷
Novartis Investigative Site, Bursa, Gorukle, Turkey

Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation

Phase 3

Active, not recruiting

Conditions: Advanced HER2+Breast Cancer

Interventions: Drug: Alpelisib matching Placebo
Drug: Alpelisib
Drug: Trastuzumab
Drug: Pertuzumab

First Posted Date: 2019-12-23

Last Posted Date: 2025-01-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 19

Registration Number: NCT04208178

Locations: 🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇺🇸
University of California LA, Los Angeles, California, United States
🇪🇸
Novartis Investigative Site, Hospitalet de LLobregat, Catalunya, Spain

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy